针对克柔念珠菌质量控制菌株的抗真菌联合用药的多实验室检测。
Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.
作者信息
Chaturvedi Vishnu, Ramani Rama, Ghannoum Mahmoud A, Killian Scott B, Holliday Nicole, Knapp Cindy, Ostrosky-Zeichner Luis, Messer Shawn A, Pfaller Michael A, Iqbal Naureen J, Arthington-Skaggs Beth A, Vazquez Jose A, Sein Tin, Rex John H, Walsh Thomas J
机构信息
Mycology Laboratory, Wadsworth Center, New York State Department of Health, 120 New Scotland Ave., Albany, NY 12208, USA.
出版信息
Antimicrob Agents Chemother. 2008 Apr;52(4):1500-2. doi: 10.1128/AAC.00574-07. Epub 2008 Jan 28.
Abstract
Candida krusei ATCC 6258 was tested by eight laboratories using 96-well plates containing checkerboard pairwise combinations of amphotericin B (AMB), posaconazole (PSC), caspofungin (CSP), and voriconazole (VRC). The methodology led to reproducible results across the laboratories. All drug combinations yielded MICs lower than the MICs of any two drugs tested singly, and combinations of AMB, PSC, CSP, and VRC were indifferent (no antagonism) by summations of fractional inhibitory concentration.
摘要
八家实验室使用含有两性霉素B（AMB）、泊沙康唑（PSC）、卡泊芬净（CSP）和伏立康唑（VRC）棋盘格两两组合的96孔板对克鲁斯念珠菌ATCC 6258进行了测试。该方法在各实验室间产生了可重复的结果。所有药物组合产生的最低抑菌浓度（MIC）均低于任何两种单独测试药物的MIC，并且通过部分抑菌浓度总和，AMB、PSC、CSP和VRC的组合无相互作用（无拮抗作用）。
相似文献
1
Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.
Antimicrob Agents Chemother. 2008 Apr;52(4):1500-2. doi: 10.1128/AAC.00574-07. Epub 2008 Jan 28.
2
Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.
Antimicrob Agents Chemother. 2011 Apr;55(4):1543-8. doi: 10.1128/AAC.01510-09. Epub 2011 Jan 31.
3
Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.
Mycopathologia. 2012 Jan;173(1):27-34. doi: 10.1007/s11046-011-9459-x. Epub 2011 Aug 13.
4
Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates.
Med Mycol. 2013 Jan;51(1):60-5. doi: 10.3109/13693786.2012.697198. Epub 2012 Jul 2.
5
In vitro activity of antifungal combinations against Candida albicans biofilms.
J Antimicrob Chemother. 2010 Feb;65(2):271-4. doi: 10.1093/jac/dkp429. Epub 2009 Dec 8.
6
Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells.
Antimicrob Agents Chemother. 2011 May;55(5):1968-74. doi: 10.1128/AAC.00959-10. Epub 2011 Feb 22.
7
Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.
J Clin Microbiol. 2002 Oct;40(10):3841-4. doi: 10.1128/JCM.40.10.3841-3844.2002.
8
Interactions of Echinocandins with Triazoles against Multidrug-Resistant .
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01056-17. Print 2017 Nov.
9
In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Chin Med J (Engl). 2010 Oct;123(19):2706-9.
10
Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A.
Ann Clin Microbiol Antimicrob. 2012 Oct 4;11:27. doi: 10.1186/1476-0711-11-27.
引用本文的文献
1
In vitro antimicrobial activity of polyhexamethylene guanidine hydrochloride and polyhexamethylene biguanide against microorganisms causing bovine mastitis.
Braz J Microbiol. 2025 Jul 2. doi: 10.1007/s42770-025-01732-8.
2
CAF to the Rescue! Potential and Challenges of Combination Antifungal Therapy for Reducing Morbidity and Mortality in Hospitalized Patients With Serious Fungal Infections.
Open Forum Infect Dis. 2024 Oct 30;11(11):ofae646. doi: 10.1093/ofid/ofae646. eCollection 2024 Nov.
3
Brazilian Red Propolis Presents Promising Anti- Activity in In Vitro and In Vivo Assays with the Ability to Modulate the Immune Response.
Molecules. 2022 Oct 27;27(21):7310. doi: 10.3390/molecules27217310.
4
Antifungal Combinations against Species: From Bench to Bedside.
J Fungi (Basel). 2022 Oct 13;8(10):1077. doi: 10.3390/jof8101077.
5
Curcumin affects function of Hsp90 and drug efflux pump of .
Front Cell Infect Microbiol. 2022 Sep 27;12:944611. doi: 10.3389/fcimb.2022.944611. eCollection 2022.
6
Multicenter Collaborative Study of the Interaction of Antifungal Combinations against Spp. by Loewe Additivity and Bliss Independence-Based Response Surface Analysis.
J Fungi (Basel). 2022 Sep 16;8(9):967. doi: 10.3390/jof8090967.
7
Role of Antifungal Combinations in Difficult to Treat Infections.
J Fungi (Basel). 2021 Sep 6;7(9):731. doi: 10.3390/jof7090731.
8
Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02195-19.
9
In vitro studies of the antibacterial activity of spp. oleoresins, sodium hypochlorite, and peracetic acid against clinical and environmental isolates recovered from a hemodialysis unit.
Antimicrob Resist Infect Control. 2018 Jan 24;7:14. doi: 10.1186/s13756-018-0307-3. eCollection 2018.
10
Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint.
Antimicrob Agents Chemother. 2015 Mar;59(3):1759-66. doi: 10.1128/AAC.04545-14. Epub 2014 Dec 15.
本文引用的文献
1
Role of antifungal susceptibility testing in patient management.
Curr Opin Infect Dis. 2006 Dec;19(6):538-43. doi: 10.1097/QCO.0b013e328010682c.
2
Resistant Microascus cirrosus pneumonia can be treated with a combination of surgery, multiple anti-fungal agents and a growth factor.
Mycopathologia. 2006 Oct;162(4):299-302. doi: 10.1007/s11046-006-0067-0.
3
New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.
Clin Infect Dis. 2006 Oct 15;43(8):1060-8. doi: 10.1086/507891. Epub 2006 Sep 8.
4
Clinical efficacy of new antifungal agents.
Curr Opin Microbiol. 2006 Oct;9(5):483-8. doi: 10.1016/j.mib.2006.08.001. Epub 2006 Aug 9.
5
Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole.
BMC Infect Dis. 2006 Feb 15;6:26. doi: 10.1186/1471-2334-6-26.
6
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.
Eur J Clin Microbiol Infect Dis. 2005 Oct;24(10):654-61. doi: 10.1007/s10096-005-0024-8.
7
Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.
Med Mycol. 2005 Mar;43(2):133-52. doi: 10.1080/13693780410001731547.
8
Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods.
Antimicrob Agents Chemother. 2005 Apr;49(4):1593-6. doi: 10.1128/AAC.49.4.1593-1596.2005.
9
Combinations of antifungal agents in therapy--what value are they?
J Antimicrob Chemother. 2004 Nov;54(5):854-69. doi: 10.1093/jac/dkh434. Epub 2004 Sep 16.
10
Combination antifungal therapy.
Antimicrob Agents Chemother. 2004 Mar;48(3):693-715. doi: 10.1128/AAC.48.3.693-715.2004.
Zotero 插件